Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Colombo

Showing results (161-170 of 219) with videos related to

Pageof 22
Sort By:
Oncogene|January 11, 2007
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cellsV Appierto, M G Villani, E Cavadini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2012
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective seriesR Fruscio, S Corso, L Ceppi, et al.
Brain : a Journal of Neurology|November 25, 2006
Surgical treatment of drug-resistant nocturnal frontal lobe epilepsyL Nobili, S Francione, R Mai, et al.
Brain : a Journal of Neurology|July 24, 2002
Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcomeL Tassi, N Colombo, R Garbelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapyG Cavaletti, G Bogliun, L Marzorati, et al.
Gynecologic Oncology|December 14, 2012
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)F Cognetti, A Bagnato, N Colombo, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
The disposition of carboplatin in ovarian cancer patientsR C Gaver, N Colombo, M D Green, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2022
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upA Oaknin, T J Bosse, C L Creutzberg, et al.
British Journal of Cancer|February 14, 2013
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trialN Colombo, D S McMeekin, P E Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionE A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, et al.
Pageof 22

Showing results (161-170 of 219) with videos related to

Sort By:
Pageof 22
Oncogene|January 11, 2007
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cellsV Appierto, M G Villani, E Cavadini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2012
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective seriesR Fruscio, S Corso, L Ceppi, et al.
Brain : a Journal of Neurology|November 25, 2006
Surgical treatment of drug-resistant nocturnal frontal lobe epilepsyL Nobili, S Francione, R Mai, et al.
Brain : a Journal of Neurology|July 24, 2002
Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcomeL Tassi, N Colombo, R Garbelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2004
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapyG Cavaletti, G Bogliun, L Marzorati, et al.
Gynecologic Oncology|December 14, 2012
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14)F Cognetti, A Bagnato, N Colombo, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1988
The disposition of carboplatin in ovarian cancer patientsR C Gaver, N Colombo, M D Green, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2022
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upA Oaknin, T J Bosse, C L Creutzberg, et al.
British Journal of Cancer|February 14, 2013
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trialN Colombo, D S McMeekin, P E Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionE A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, et al.
Pageof 22